Safety of Biological Medicinal Products

LFB Group has always made the biological safety of its medicinal products a top priority. In particular, it has pioneered nanofiltration, a technique used to eliminate pathogenic agents. Both the French authorities and the key European and international bodies have recognized the efficacy of this technique, particularly for the elimination of viruses and prions. In the area of Unconventional Transmissible Agents (UTAs) such as “prions”, LFB Group has patented a validation method for the efficacy of prion elimination based on an in vitro cell test.

LFB Group is developing this method at its Biological Safety Laboratory in the “Neuroprion” Platform of CEA, the French Atomic Energy Commission. In 2001, LFB set up ISAC, the International Safety & Advisory Committee of International Experts led by Professor Paul Brown, a world-renowned specialist in prion diseases, to strengthen its biological safety strategy. LFB S.A. is also a founding member of the Alliance BioSecure Foundation, whose mission is to grow the understanding and management of public health risks associated with current or emerging microbiological agents and prions, in particular.